carlisle medical
Refill Requests shipment tracking contact carlisle medical
knowledge center
industry news
07/17/2017
Louisiana Enacts New Laws Regarding Opioid Prescribing Limits
Louisiana joined several states in enacting new laws limiting the days’ supply of a new opioid medication that can be dispensed. Act 82 states that for adults in outpatient settings with acute conditions, no more than a seven-day supply on a... Full Story
07/10/2017
Endo Pharmaceuticals, Inc. Announces Withdrawal of Opana ER
Endo Pharmaceuticals announced it would be voluntarily withdrawing Opana ER (Oxymorphone ER) from the market. In June, the FDA requested that Endo remove Opana due to public health concerns regarding abuse of the medication. The FDA stated “after... Full Story
04/25/2017
Gabapentin to Become a Controlled Substance in Kentucky
Kentucky will become the first state to change gabapentin to a Schedule V controlled substance, effective July 1, 2017. Current FDA-approved indications for gabapentin are post-herpetic neuralgia and seizures. However, gabapentin is most often... Full Story
02/28/2017
New Jersey Governor Signs Opioid Restriction Law
New Jersey Governor, Chris Christie, signed new legislation recently to help curb the opioid epidemic in his state. The new legislation, Bill 3, limits initial opioid prescriptions for acute pain to a five-day supply and requires the prescriber to... Full Story
01/20/2017
FDA Approves Vantrela ER
Vantrela ER (Hydrocodone Bitartrate) from Teva Pharmaceuticals has recently been granted approval from the FDA. Vantrela ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for... Full Story
11/30/2016
Pennsylvania Passes Legislation Aimed at Reducing Opioid Abuse
Pennsylvania joins several states, including New York and Rhode Island, that have passed new opioid regulations aimed at reducing opioid abuse and deaths from overdoses. In November Pennsylvania Governor, Tom Wolf, signed several bills that either... Full Story
11/11/2016
DEA Reduces Amount of Opioid Controlled Substances in 2017
The U.S. Drug Enforcement Administration (DEA) has published a Final Order on its website stating it will be reducing the amount of opioid medications that may be manufactured in the United States in 2017 by 25%. The manufacturing of certain opioid... Full Story
09/06/2016
FDA Approves Troxyca ER
Troxyca ER (Oxycodone/Naltrexone) is a new Schedule II opioid from Pfizer Pharmaceuticals that recently received approval from the FDA (U.S. Food and Drug Administration). Troxyca ER is indicated for the management of pain severe enough to require... Full Story
08/11/2016
NY: Initial Opioid Prescribing Limit Reduced to Seven Days for Acute Pain
The State of New York recently enacted several new measures to address the heroin and opioid abuse crisis in New York. One part of this legislation is aimed at reducing the overprescribing of opioids in acute pain situations.... Full Story
05/04/2016
New Schedule II Opioids Introduced
Oxaydo™, a Schedule II opioid, is the first and only immediate-release formulation of Oxycodone HCL that discourages intranasal abuse and is indicated for the management of acute and chronic moderate to severe pain, where the use of an opioid... Full Story
02/19/2016
Tennessee Publishes Rules on Treatment Guidelines and Drug Formulary
Tennessee Publishes Rules on Treatment Guidelines and Drug Formulary The Tennessee Attorney General has approved new treatment guidelines and a closed drug formulary proposed by the Tennessee Bureau of Workers’ Compensation. The rule will next go... Full Story
01/01/2016
2016 Georgia Update – Case Management Changes
Effective January 1, 2016 the Georgia State Board of Workers’ Compensation has implemented a change to Rule 200.2. To view and download the minutes from the Georgia State Board of Workers’ Compensation, click the link... Full Story
11/20/2014
Launch of Hysingla ER
The Federal Drug Administration (FDA) has approved the release of Hysingla ER, the first hard-to-abuse version of hydrocodone. Hysingla ER is an extended release opioid used to treat severe pain and should not be used for as-needed pain relief. The... Full Story
08/22/2014
New Rule for Hydrocodone
The U. S. Drug Enforcement Agency (DEA) has published its final rule for hydrocodone combination products, changing its drug classification from a Schedule III to a Schedule II medication, as defined in the Controlled Substances Act. Hydrocodone is... Full Story
07/23/2014
FDA Approves New Extended-Release Oxycodone with Abuse-Deterrent Properties
"Today, the U.S. Food and Drug Administration approved Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended-release tablets), an extended-release/long-acting (ER/LA) opioid analgesic to treat pain severe enough to require daily,... Full Story
07/23/2014
Louisiana: Carisoprodol (Soma) Placed in Schedule II Classification
Act 397 (SB 618) of 2014 Legislature - effective August 1. 2014. This law places carisoprodol (Soma) products with the exception of the combination product with codeine) in Schedule II of the Louisiana Uniform Controlled Substances Law. These... Full Story
07/02/2014
DEA Finalizes Rule to Schedule Tramadol
On July 2, 2014, the Drug Enforcement Administration (DEA) published in the Federal Register the final rule placing tramadol into Schedule IV of the Controlled Substances Act. This rule will become effective on August 18, 2014. At this time, all... Full Story
05/15/2014
FDA Recommends Decreased Dosage Of Lunesta
The U.S. Food and Drug Administration (FDA) has released a Safety Announcement which states: “The U.S. Food and Drug Administration (FDA) is warning that the insomnia drug Lunesta (eszopiclone) can cause next-day impairment of driving and other... Full Story
01/10/2014
REMOVAL OF CODEINE FROM THE MARKET
In its January 10, 2014 notice in the Federal Register, the FDA ordered drug companies to stop the manufacturing of unapproved products from the following prescription drug list: > Single-ingredient codeine sulfate oral tablets; > ... Full Story
10/18/2013
FDA Approval for ZORVOLEX™
October 18, 2013 – Iroko Pharmaceuticals, LLC, announced that the FDA had approved ZORVOLEX™ (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID), for the treatment of mild to moderate acute pain in adults. ZORVOLEX™ was approved at... Full Story
04/17/2013
FDA bans generic version of Oxycontin
On the day when the patent for the original version of OxyContin was set to expire the Food and Drug Administration said Tuesday that it would not approve generic versions of the powerful narcotic Oxycontin. The move represents a victory for... Full Story
03/12/2013
Changes to the Controlled Substance Schedules - New York
Changes to the Controlled Substance Schedules in Section 3306 of the New York State Public Health Law per the Bureau of Narcotic Enforcement (http://www.health.ny.gov/professionals/narcotic/), effective February 23, 2013, the following changes will... Full Story
02/06/2013
Illinois - Final Physician-Dispensed Pharmacy Rule Published
The IWCC's final repackaged drug repricing methodology was published in the December 7 edition of the Illinois Register. As we covered in our 11/20/2012 post, the effective date of the change is November 20, 2012. The Medical Fee Advisory Board... Full Story
11/19/2012
Notes from the Pharmacists: Suboxone® Tablets
Suboxone® (buprenorphine /naloxone) tablets were developed to prevent abuse. The naloxone in the Suboxone® tablet is there to discourage people from dissolving the tablet and injecting it. When a Suboxone® Tablet is placed under the tongue, as... Full Story
 
Company News
Generic Releases
Industry Related News
Industry Related Links
Newsletter Subscription
Newsletter Login
 
 
 
 
 
© Copyright 2017 Carlisle & Medical, Inc.
Twitter Twitter Twitter Twitter
disclaimer site map disclaimer